Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
34.97 USD | -3.42% |
|
-1.64% | -11.49% |
06-18 | Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target | MT |
06-11 | Celldex Therapeutics Insider Sold Shares Worth $1,586,844, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.49% | 2.39B | |
+31.14% | 52.73B | |
+37.72% | 39B | |
-9.16% | 38.52B | |
+26.27% | 30.38B | |
-11.17% | 26.39B | |
+10.95% | 26.08B | |
+44.84% | 14.15B | |
+33.25% | 12.6B | |
-5.39% | 11.51B |
- Stock Market
- Equities
- CLDX Stock
- News Celldex Therapeutics, Inc.
- Celldex Therapeutics Insider Sold Shares Worth $525,873, According to a Recent SEC Filing